Hypoxia-Induced Cytotoxic Drug Resistance in Osteosarcoma Is Independent of HIF-1Alpha

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Adamski, Jennifer ^a,b,c   Price, Andrew ^a   Dive, Caroline ^a,b   Makin, Guy ^a,b,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COBALT CHLORIDE; DOXORUBICIN; ETOPOSIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; SERINE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; HUMAN; HYPOXIA; HYPOXIA INDUCED CYTOTOXIC DRUG RESISTANCE; IC 50; IN VITRO STUDY; OSTEOSARCOMA; OSTEOSARCOMA CELL; PROTEIN PHOSPHORYLATION; TREATMENT OUTCOME; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL HYPOXIA; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; OSTEOSARCOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84879003070     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065304     Document Type: Article

References (71)

1. Stiller CA, (2007) International patterns of cancer incidence in adolescents. Cancer Treat Rev 33: 631-645.
2. Gatta G, Corazziari I, Magnani C, Peris-Bonet R, Roazzi P, et al. (2003) Childhood cancer survival in Europe. Ann Oncol 14Suppl 5: v119-127.
3. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, et al. (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314: 1600-1606.
4. Harting MT, Blakely ML, Jaffe N, Cox CS Jr, Hayes-Jordan A, et al. (2006) Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg 41: 194-199.
5. Meyers PA, Heller G, Healey JH, Huvos A, Applewhite A, et al. (1993) Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 11: 449-453.
6. Brown LM, Cowen RL, Debray C, Eustace A, Erler JT, et al. (2006) Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol 69: 411-418.
7. Dai S, Huang ML, Hsu CY, Chao KS, (2003) Inhibition of hypoxia inducible factor 1alpha causes oxygen-independent cytotoxicity and induces p53 independent apoptosis in glioblastoma cells. Int J Radiat Oncol Biol Phys 55: 1027-1036.
8. Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, et al. (2004) Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and-independent mechanisms and contributes to drug resistance. Mol Cell Biol 24: 2875-2889.
9. Ravizza R, Molteni R, Gariboldi MB, Marras E, Perletti G, et al. (2009) Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil. Eur J Cancer 45: 890-898.
10. Song X, Liu X, Chi W, Liu Y, Wei L, et al. (2006) Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 58: 776-784.
11. Sullivan R, Pare GC, Frederiksen LJ, Semenza GL, Graham CH, (2008) Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther 7: 1961-1973.
12. Yokoi K, Fidler IJ, (2004) Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 10: 2299-2306.
13. Hussein D, Estlin EJ, Dive C, Makin GW, (2006) Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther 5: 2241-2250.
14. Kilic M, Kasperczyk H, Fulda S, Debatin KM, (2007) Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 26: 2027-2038.
15. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, et al. (2000) Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6: 572-577.
16. Mizobuchi H, Garcia-Castellano JM, Philip S, Healey JH, Gorlick R, (2008) Hypoxia markers in human osteosarcoma: an exploratory study. Clin Orthop Relat Res 466: 2052-2059.
17. Yang QC, Zeng BF, Dong Y, Shi ZM, Jiang ZM, et al. (2007) Overexpression of hypoxia-inducible factor-1alpha in human osteosarcoma: correlation with clinicopathological parameters and survival outcome. Jpn J Clin Oncol 37: 127-134.
18. Chen WL, Feng HJ, Li HG, (2008) Expression and significance of hypoxemia-inducible factor-1alpha in osteosarcoma of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106: 254-257.
19. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, et al. (1997) A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U S A 94: 4273-4278.
20. Wang GL, Jiang BH, Rue EA, Semenza GL, (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92: 5510-5514.
21. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
22. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, et al. (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62: 3387-3394.
23. Sullivan R, Graham CH, (2009) Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. Mol Cancer Ther 8: 1702-1713.
24. Liu XW, Su Y, Zhu H, Cao J, Ding WJ, et al. (2010) HIF-1alpha-dependent autophagy protects HeLa cells from fenretinide (4-HPR)-induced apoptosis in hypoxia. Pharmacol Res 62: 416-425.
25. Hao J, Song X, Song B, Liu Y, Wei L, et al. (2008) Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther 15: 449-455.
26. Huang L, Ao Q, Zhang Q, Yang X, Xing H, et al. (2010) Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha. J Cancer Res Clin Oncol 136: 447-456.
27. Liu L, Ning X, Sun L, Zhang H, Shi Y, et al. (2008) Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci 99: 121-128.
28. Roberts DL, Williams KJ, Cowen RL, Barathova M, Eustace AJ, et al. (2009) Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells. Br J Cancer 101: 1290-1297.
29. Sermeus A, Cosse JP, Crespin M, Mainfroid V, de Longueville F, et al. (2008) Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity. Mol Cancer 7: 27.
30. Achison M, Hupp TR, (2003) Hypoxia attenuates the p53 response to cellular damage. Oncogene 22: 3431-3440.
31. Cosse JP, Ronvaux M, Ninane N, Raes MJ, Michiels C, (2009) Hypoxia-induced decrease in p53 protein level and increase in c-jun DNA binding activity results in cancer cell resistance to etoposide. Neoplasia 11: 976-986.
32. Wang D, Zhu Q, Zhang X, Zhang L, He Q, et al. (2010) Hypoxia promotes etoposide (VP-16) resistance in neuroblastoma CHP126 cells. Pharmazie 65: 51-56.
33. Zhang L, Hill RP, (2004) Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis. Cancer Res 64: 4180-4189.
34. Boller YC, Brandes LM, Russell RL, Lin ZP, Patierno SR, et al. (2000) Prostaglandin A1 inhibits stress-induced NF-kappaB activation and reverses resistance to topoisomerase II inhibitors. Oncol Res 12: 383-395.
35. Chen J, Kobayashi M, Darmanin S, Qiao Y, Gully C, et al. (2009) Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene 28: 2581-2592.
36. Piret JP, Cosse JP, Ninane N, Raes M, Michiels C, (2006) Hypoxia protects HepG2 cells against etoposide-induced apoptosis via a HIF-1-independent pathway. Exp Cell Res 312: 2908-2920.
37. Rohwer N, Dame C, Haugstetter A, Wiedenmann B, Detjen K, et al. (2010) Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS One 5: e12038.
38. Schnitzer SE, Schmid T, Zhou J, Brune B, (2006) Hypoxia and HIF-1alpha protect A549 cells from drug-induced apoptosis. Cell Death Differ 13: 1611-1613.
39. Selvendiran K, Bratasz A, Kuppusamy ML, Tazi MF, Rivera BK, et al. (2009) Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. Int J Cancer 125: 2198-2204.
40. Park SY, Billiar TR, Seol DW, (2002) Hypoxia inhibition of apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Biochem Biophys Res Commun 291: 150-153.
41. Carroll VA, Ashcroft M, (2006) Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66: 6264-6270.
42. Alvarez-Tejado M, Naranjo-Suarez S, Jimenez C, Carrera AC, Landazuri MO, et al. (2001) Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J Biol Chem 276: 22368-22374.
43. Chen EY, Mazure NM, Cooper JA, Giaccia AJ, (2001) Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res 61: 2429-2433.
44. Lee SM, Lee CT, Kim YW, Han SK, Shim YS, et al. (2006) Hypoxia confers protection against apoptosis via PI3K/Akt and ERK pathways in lung cancer cells. Cancer Lett 242: 231-238.
45. Damia G, Filiberti L, Vikhanskaya F, Carrassa L, Taya Y, et al. (2001) Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia 3: 10-16.
46. Lowe SW, Ruley HE, Jacks T, Housman DE, (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967.
47. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, et al. (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91.
48. Wang J, Biju MP, Wang MH, Haase VH, Dong Z, (2006) Cytoprotective effects of hypoxia against cisplatin-induced tubular cell apoptosis: involvement of mitochondrial inhibition and p53 suppression. J Am Soc Nephrol 17: 1875-1885.
49. Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, et al. (2009) Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res 69: 9056-9064.
50. Kalra R, Jones AM, Kirk J, Adams GE, Stratford IJ, (1993) The effect of hypoxia on acquired drug resistance and response to epidermal growth factor in Chinese hamster lung fibroblasts and human breast-cancer cells in vitro. Int J Cancer 54: 650-655.
51. Teicher BA, Lazo JS, Sartorelli AC, (1981) Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41: 73-81.
52. Song J, Qu Z, Guo X, Zhao Q, Zhao X, et al. (2009) Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells. Autophagy 5: 1131-1144.
53. Koch S, Mayer F, Honecker F, Schittenhelm M, Bokemeyer C, (2003) Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro. Br J Cancer 89: 2133-2139.
54. Dong Z, Venkatachalam MA, Wang J, Patel Y, Saikumar P, et al. (2001) Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent mechanisms. J Biol Chem 276: 18702-18709.
55. Graziani I, Eliasz S, De Marco MA, Chen Y, Pass HI, et al. (2008) Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway. Cancer Res 68: 9678-9685.
56. Vivanco I, Sawyers CL, (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
57. Clark AS, West K, Streicher S, Dennis PA, (2002) Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1: 707-717.
58. Hovelmann S, Beckers TL, Schmidt M, (2004) Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells. Br J Cancer 90: 2370-2377.
59. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, et al. (2008) Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 68: 6271-6280.
60. Dai T, Zheng H, Fu GS, (2008) Hypoxia confers protection against apoptosis via the PI3K/Akt pathway in endothelial progenitor cells. Acta Pharmacol Sin 29: 1425-1431.
61. Risbud MV, Fertala J, Vresilovic EJ, Albert TJ, Shapiro IM, (2005) Nucleus pulposus cells upregulate PI3K/Akt and MEK/ERK signaling pathways under hypoxic conditions and resist apoptosis induced by serum withdrawal. Spine (Phila Pa 1976) 30: 882-889.
62. Blancher C, Moore JW, Robertson N, Harris AL, (2001) Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res 61: 7349-7355.
63. Sabbatini P, McCormick F, (1999) Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis. J Biol Chem 274: 24263-24269.
64. Hammond EM, Giaccia AJ, (2005) The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun 331: 718-725.
65. Florenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, et al. (1994) MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 86: 1297-1302.
66. Jackson MW, Agarwal MK, Agarwal ML, Agarwal A, Stanhope-Baker P, et al. (2004) Limited role of N-terminal phosphoserine residues in the activation of transcription by p53. Oncogene 23: 4477-4487.
67. Yuan XW, Zhu XF, Huang XF, Sheng PY, He AS, et al. (2007) Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis. Acta Pharmacol Sin 28: 1835-1841.
68. Vichai V, Kirtikara K, (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1: 1112-1116.
69. Klymenko T, Brandenburg M, Morrow C, Dive C, Makin G, (2011) The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells. Mol Cancer Ther 10: 2373-2383.
70. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
71. Chau NM, Rogers P, Aherne W, Carroll V, Collins I, et al. (2005) Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. Cancer Res 65: 4918-4928.